Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Public ClinicalTrials.gov record NCT05425745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies
Study identification
- NCT ID
- NCT05425745
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Enrollment
- 354 participants
Conditions and interventions
Conditions
Interventions
- Obicetrapib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2022
- Primary completion
- May 27, 2024
- Completion
- May 27, 2024
- Last update posted
- Jun 10, 2025
2022 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 01022 | Jonesboro | Arkansas | 72401 | — |
| Site 01015 | Toluca Lake | California | 91602 | — |
| Site 01009 | Sarasota | Florida | 34230 | — |
| Site 01023 | Boise | Idaho | 83702 | — |
| Site 01018 | Chicago | Illinois | 60602 | — |
| Site 01012 | Iowa City | Iowa | 52240 | — |
| Site 01007 | Baton Rouge | Louisiana | 70809 | — |
| Site 01005 | Port Gibson | Mississippi | 39105 | — |
| Site 01006 | St Louis | Missouri | 63130 | — |
| Site 01011 | Lincoln | Nebraska | 68510 | — |
| Site 01004 | Norfolk | Nebraska | 68701 | — |
| Site 01002 | Morristown | New Jersey | 07960 | — |
| Site 01010 | New Providence | New Jersey | 07901 | — |
| Site 01001 | North Massapequa | New York | 11758 | — |
| Site 01020 | Morganton | North Carolina | 28655 | — |
| Site 01019 | Winston-Salem | North Carolina | 27157 | — |
| Site 01008 | Chattanooga | Tennessee | 37405 | — |
| Site 01016 | El Paso | Texas | 79905 | — |
| Site 01013 | Houston | Texas | 76706 | — |
| Site 01014 | Suffolk | Virginia | 23434 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05425745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05425745 live on ClinicalTrials.gov.